CLINICAL_TRIALS
trial_result
· 2026-01-13
Clinical Trial Update: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) [Phase 2]
Summary
Results from a Phase 2 PORTOLA trial of Zetomipzomib (KZR-616) in autoimmune hepatitis have been completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kezar Life Sciences, Inc. | Conditions: Autoimmune Hepatitis | Phase 2 | Status: COMPLETED | Results posted: 2026-01-13